Received Feb 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 1 | J3952 | — |
the adult dose was given to an 18-year-old; the adult dose was given to an 18-year-old; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult product administered to child in a 18-year-old female patient who received HBV (Engerix B adult) (batch number J3952, expiry date 01-DEC-2026) for prophylaxis. On 14-JAN-2025, the patient received the 1st dose of Engerix B adult. On 14-JAN-2025, an unknown time after receiving Engerix B adult, the patient experienced adult product administered to child (Verbatim: the adult dose was given to an 18-year-old) and overdose (Verbatim: the adult dose was given to an 18-year-old). The outcome of the adult product administered to child and overdose were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 14-JAN-2025 Pharmacist reported that the adult dose was given to an 18-year-old, which led to adult product administered to child and overdose. According to reporter, it was the 1st dose of the series for such patient.